Ankur Dhingra bought $495K of Illumina (ILMN)
Executed May 12 2025, disclosed May 14 2025, 2 days later.
Over the 21 trading sessions from the disclosed entry session (May 14 2025), the stock returned +9.8% (delay-adjusted); from the execution session (May 12 2025), +11.0%. Derived: entry at the session's open, exit at the close 20 sessions later.
Ankur Dhingra (SVP, Chief Financial Officer) filed 1 Form 4 report in the past 24 months (1 purchase, 0 sales), most often in Illumina, Inc. (ILMN). Across 1 priced purchase filing, the average 21-session return was +11.0% from execution and +9.8% from disclosure (delay-adjusted; derived). The largest single filing was $495K of ILMN (6,100 sh × $81.21, as filed), executed May 12 2025.
Healthcare · Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→